Strongyloides pneumonia.

Am J Trop Med Hyg

Published: August 2012

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3414549PMC
http://dx.doi.org/10.4269/ajtmh.2012.12-0108DOI Listing

Publication Analysis

Top Keywords

strongyloides pneumonia
4
strongyloides
1

Similar Publications

Strongyloides hyperinfection and disseminated infections are usually associated with immunosuppression; these severe manifestations occur in a minority of cases. The use of immunosuppressants such as corticosteroids and Baricitinib for treating COVID-19 pneumonia can be responsible for patients' immunosuppression and cause Strongyloides hyperinfection syndrome. The chance increases when the patient belongs to countries or regions where chronic infection with Strongyloides is more prevalent.

View Article and Find Full Text PDF

Parasitic Infections in Pulmonary and ICU Patients: Presentation, Diagnosis, and Treatment.

Chest

November 2024

Infectious Diseases Division, Department of Internal Medicine, University of Texas Medical Branch, Galveston, TX. Electronic address:

Article Synopsis
  • Parasitic infections in the U.S. primarily affect immigrants and travelers, often leading to delayed diagnoses by physicians unfamiliar with these diseases.
  • Nearly 2,000 cases of imported malaria occur annually, with severe symptoms that can mimic bacterial sepsis, and treatment requires careful management to improve survival.
  • Strongyloidiasis, endemic in warm regions, can stay dormant for years and worsen if corticosteroids are used, while other infections like cystic echinococcosis and paragonimus present with specific respiratory symptoms and are found in various global regions, including parts of North America.
View Article and Find Full Text PDF

High prevalence of anti-Strongyloides antibody in SARS-CoV-2-infected human sera in a Thai hospital: Rapid serological screening.

J Infect Public Health

August 2024

Mekong Health Science Research Institute, Khon Kaen University, Khon Kaen 40002, Thailand; Department of Parasitology, Faculty of Medicine, Khon Kaen University, Khon Kaen 40002, Thailand.

Article Synopsis
  • - COVID-19, caused by SARS-CoV-2, can lead to severe lung issues and systemic dysfunction, prompting the use of immunosuppressive treatments that risk worsening existing infections like strongyloidiasis.
  • - A study in Thailand found a significant prevalence of anti-Strongyloides IgG antibodies in 39.4% of 297 COVID-19 patients, suggesting a potential relationship between these infections and COVID-19.
  • - Researchers recommend using a rapid immunochromatographic test for strongyloidiasis screening in critically ill COVID-19 patients, coupled with immediate treatment to prevent severe complications in those at risk.
View Article and Find Full Text PDF
Article Synopsis
  • CT scans revealed pneumatosis intestinalis, and his respiratory condition worsened as Strongyloides stercoralis was found, leading to a diagnosis of hyperinfection syndrome and acute respiratory distress syndrome.
  • The late treatment with ivermectin was unsuccessful, and the patient ultimately died from multiple organ failure, emphasizing the need to monitor for chronic strongyloidiasis in COVID-19 patients in endemic regions who are on steroids.
View Article and Find Full Text PDF

Background: It is well-documented that using immunosuppressive drugs such as corticosteroids or cytokine blockers in treating coronavirus disease 2019 (COVID-19) increases the risk of co-infections. Here we systematically summarized the cases of COVID-19-associated parasitic infections (CAPIs) in Iran.

Methods: From 19 February 2020 to 10 May 2023, all studies on Iranian patients suffering from CAPIs were collected from several databases using a systematic search strategy.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!